Cargando…

In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist

Solid rationales are still present for the identification of synthetic ligands to simultaneously target multiple PPAR subtypes for the treatment of T2DM. The purpose of this study was to characterize the in vitro and in vivo differential effects of chiglitazar, a non-TZD type of PPAR pan-agonist cur...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, B. K., Ning, Z. Q., Li, Z. B., Shan, S., Pan, D. S., Ko, B. C. B., Li, P. P., Shen, Z. F., Dou, G. F., Zhang, B. L., Lu, X. P., Gao, Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486420/ https://www.ncbi.nlm.nih.gov/pubmed/23150725 http://dx.doi.org/10.1155/2012/546548

Ejemplares similares

Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ
por: Pan, De-Si, et al.
Publicado: (2017)

To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations
por: Sullivan, Holli-Joi, et al.
Publicado: (2020)

Personalized glucose-lowering effect of chiglitazar in type 2 diabetes
por: Huang, Qi, et al.
Publicado: (2023)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats
por: Khazaei, M., et al.
Publicado: (2012)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis
por: Lin, Chu, et al.
Publicado: (2023)

The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome
por: Huang, Yan, et al.
Publicado: (2017)

Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes
por: Zhou, Yunting, et al.
Publicado: (2022)

Role of an Indole-Thiazolidine Molecule PPAR Pan-Agonist and COX Inhibitor on Inflammation and Microcirculatory Damage in Acute Gastric Lesions
por: Santin, José Roberto, et al.
Publicado: (2013)

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
por: Tenenbaum, Alexander, et al.
Publicado: (2005)

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2016)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
por: Wang, Xue-Jiao, et al.
Publicado: (2014)

The PPAR pan-agonist tetradecylthioacetic acid promotes redistribution of plasma cholesterol towards large HDL
por: Lundåsen, Thomas, et al.
Publicado: (2020)

Polylactide Nanocapsules Attenuate Adverse Cardiac Cellular Effects of Lyso-7, a Pan-PPAR Agonist/Anti-Inflammatory New Thiazolidinedione
por: Garcia, Giani M., et al.
Publicado: (2021)

Impact of between-tissue differences on pan-cancer predictions of drug sensitivity
por: Lloyd, John P., et al.
Publicado: (2021)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Fish Oil and the Pan-PPAR Agonist Tetradecylthioacetic Acid Affect the Amino Acid and Carnitine Metabolism in Rats
por: Bjørndal, Bodil, et al.
Publicado: (2013)

Molecular Docking Identifies 1,8-Cineole (Eucalyptol) as A Novel PPARγ Agonist That Alleviates Colon Inflammation
por: Venkataraman, Balaji, et al.
Publicado: (2023)

PPAR Agonists for the Prevention and Treatment of Lung Cancer
por: Lakshmi, Sowmya P., et al.
Publicado: (2017)

Global transcriptome analysis to identify critical genes involved in the pathology of osteoarthritis
por: Zhang, X., et al.
Publicado: (2018)

CRISPR-mediated BMP9 ablation promotes liver steatosis via the down-regulation of PPARα expression
por: Yang, Z., et al.
Publicado: (2020)

Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures
por: Oyama, Takuji, et al.
Publicado: (2009)

Myelin Disruption, Neuroinflammation, and Oxidative Stress Induced by Sulfite in the Striatum of Rats Are Mitigated by the pan-PPAR agonist Bezafibrate
por: Glänzel, Nícolas Manzke, et al.
Publicado: (2023)

Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancer
por: Tan, J, et al.
Publicado: (2014)

Inhibition of Carrageenan-Induced Cutaneous Inflammation by PPAR Agonists Is Dependent on Hepatocyte-Specific Retinoid X ReceptorAlpha
por: Wan, Yu-Jui Yvonne, et al.
Publicado: (2006)

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis
por: Derrett-Smith, Emma, et al.
Publicado: (2021)

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
por: Treacy, Maxwell P, et al.
Publicado: (2012)

The In Vitro and In Vivo Anti-Inflammatory Effects of a Phthalimide PPAR-γ Agonist
por: Su, Mingzhi, et al.
Publicado: (2017)

Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα + γ Agonists
por: Oleksiewicz, Martin B., et al.
Publicado: (2008)

Novel PPAR Pan Agonist, ZBH Ameliorates Hyperlipidemia and Insulin Resistance in High Fat Diet Induced Hyperlipidemic Hamster
por: Chen, Wei, et al.
Publicado: (2014)

Newly identified respiratory viruses associated with acute lower respiratory tract infections in children in Lanzou, China, from 2006 to 2009
por: Jin, Y., et al.
Publicado: (2011)

Metabolomics dataset of PPAR-pan treated rat liver
por: Ament, Zsuzsanna, et al.
Publicado: (2016)

Single-photon property characterization of 1.3 μm emissions from InAs/GaAs quantum dots using silicon avalanche photodiodes
por: Zhou, P. Y., et al.
Publicado: (2014)

Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer
por: Dong, D, et al.
Publicado: (2019)

Novel glitazones as PPARγ agonists: molecular design, synthesis, glucose uptake activity and 3D QSAR studies
por: Mandal, Subhankar P., et al.
Publicado: (2018)

An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1
por: Zhang, Z, et al.
Publicado: (2013)

PPAR Agonists and Cardiovascular Disease in Diabetes
por: Calkin, Anna C., et al.
Publicado: (2008)

PPAR Pan Agonist MHY2013 Alleviates Renal Fibrosis in a Mouse Model by Reducing Fibroblast Activation and Epithelial Inflammation
por: Son, Minjung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pbng76j22ad5q4do9l2bkelnl6